Yang Grace Meijuan, Ke Yu, Ng Xin Hui, Neo Patricia Soek Hui, Cheung Yin Bun
Division of Supportive and Palliative Care, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore, 168583, Singapore.
Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore, Singapore.
Support Care Cancer. 2025 Mar 5;33(3):249. doi: 10.1007/s00520-025-09311-1.
To deliver timely palliative care in response to supportive and palliative care needs as they arise, we developed a model called "Supportive and Palliative care Review Kit in Locations Everywhere" (SPARKLE), which comprises regular remote symptom monitoring using the Integrated Palliative care Outcome Scale (IPOS); early identification and prompt treatment of palliative care symptoms and concerns identified; and referral to specialist palliative care if follow-up is required.
A prospective randomized controlled trial of SPARKLE versus usual care was conducted among patients with advanced cancers. The primary endpoint was Functional Assessment of Cancer Therapy-General (FACT-G) scores at 16 weeks post randomization.
A total of 239 patients were randomized-119 patients to usual care and 120 patients to SPARKLE intervention. There was no significant difference in total FACT-G score (baseline-adjusted difference 0.8, 95% CI - 3.5 to 5.1, p = 0.73). Physical well-being was better in the SPARKLE intervention group compared to the usual care group (baseline-adjusted difference 1.9, 95%CI 0.4 to 3.4, p = 0.01). There were no significant differences in the other domain scores. There were no differences in palliative care referrals, occurrence of emergency department visits, or hospital admissions.
Although there was no significant difference in overall quality of life, better physical symptom control could have been achieved through proactive identification and treatment of symptoms and concerns by the SPARKLE nurse. Further studies are warranted to evaluate how various components of palliative care service models impact clinical outcomes.
ClinicalTrials.gov identifier: NCT04242251. Date of registration: 23 January 2020.
为及时提供姑息治疗以应对出现的支持性和姑息治疗需求,我们开发了一种名为“随时随地支持性和姑息治疗评估工具包”(SPARKLE)的模式,该模式包括使用姑息治疗综合结果量表(IPOS)进行定期远程症状监测;对识别出的姑息治疗症状和问题进行早期识别和及时治疗;以及在需要随访时转诊至专科姑息治疗。
在晚期癌症患者中进行了一项SPARKLE与常规护理对比的前瞻性随机对照试验。主要终点是随机分组后16周时的癌症治疗功能评估通用量表(FACT-G)得分。
共有239例患者被随机分组,119例患者接受常规护理,120例患者接受SPARKLE干预。FACT-G总分无显著差异(基线调整差异为0.8,95%置信区间为-3.5至5.1,p = 0.73)。与常规护理组相比,SPARKLE干预组的身体幸福感更好(基线调整差异为1.9,95%置信区间为0.4至3.4,p = 0.01)。其他领域得分无显著差异。姑息治疗转诊、急诊就诊次数或住院次数方面无差异。
尽管总体生活质量无显著差异,但通过SPARKLE护士对症状和问题进行主动识别和治疗,可能实现更好的身体症状控制。有必要进一步开展研究,以评估姑息治疗服务模式的各个组成部分如何影响临床结局。
ClinicalTrials.gov标识符:NCT04242251。注册日期:2020年1月23日。